Orally Disintegrating Tablet (ODT)
TASCENSO ODT® (fingolimod) is the first FDA-approved MS treatment available as an easy-to-swallow, orally disintegrating tablet. It is the same proven fingolimod you are familiar with, but in a unique ODT formulation,1 accompanied by Cycle Vita™, our support platform dedicated to providing support to all your eligible* patients.
With TASCENSO ODT, it’s time for convenience.
Orally Disintegrating Tablet (ODT)
TASCENSO ODT is the first FDA-approved MS treatment available as an easy-to-swallow, orally disintegrating tablet. It is the same proven fingolimod you are familiar with, but in a unique ODT formulation,1 accompanied by Cycle Vita, our support platform dedicated to providing support to all your eligible* patients.
With TASCENSO ODT, it’s time for convenience.
Dissolves on the tongue in seconds
Can be taken with or without water
Manufactured in the UK with each and every batch tested and verified
Not a generic2
Not substitutable at the pharmacy level2
Can be taken with or without food
No special storage conditions are required, the product should be stored at room temperature (68°F to 77°F) and protected from moisture1
Available as 0.25 mg and 0.5 mg orally disintegrating tablets
During a study of TASCENSO ODT
100%
of participants agreed TASCENSO ODT was easy to tolerate3
89%
of participants agreed they had an overall favorable opinion of TASCENSO ODT3
100%
of participants felt TASCENSO ODT left a pleasant taste3
82%
of participants agreed TASCENSO ODT had no bitter after-taste3

During a study of TASCENSO ODT
100%
of participants agreed TASCENSO ODT was easy to tolerate.2
89%
of participants agreed they had an overall favorable opinion of TASCENSO ODT.2
100%
of participants felt TASCENSO ODT left a pleasant taste.2
82%
of participants agreed TASCENSO ODT had no bitter after-taste.2

References
1. TASCENSO ODT (fingolimod). Prescribing Information. Cycle Pharmaceuticals Ltd.
2. FDA., 2024. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. Available at: https://www.accessdata.fda.gov/scripts/cder/ob/index.cfm [Accessed: August 27 2024].
3. Data on file: REF-00068
*Some areas of support may not be accessible to all patients. Eligibility criteria may apply to ensure compliance with all applicable federal and state requirements, and benefits may be limited to commercially insured patients only. For more detailed information about eligibility, terms and conditions, please contact the Cycle Vita team at 888-360-8482.
